Project: Role of metals and metal containing biomolecules in neurodegenerative diseases such as Alzheimer’s disease

New and improved tests will allow patients to access effective treatment through earlier diagnosis Over 6 million people are affected by neurodegenerative diseases in the EU and this number is set to double over the next 20 years. Early diagnosis of Alzheimer’s disease, the most common form of neurodegeneration, can help patients access effective treatments and sources of support, but studies suggest only half of people with the condition have been diagnosed and these cases are often only identified in the advanced stages. One of the key reasons for this is the lack of accuracy involved in the measurement of biomarkers used to indicate Alzheimer’s disease. This project will use the achievements of EMRP project HLT05 Metallomics to improve this accuracy by establishing new reference measurement procedures for established biomarkers in cerebrospinal fluid, found in the brain and spine, while also introducing procedures for potential new blood-based biomarkers. This will support reliable, comparable measurements in current diagnostic tests and further the development of population-based screening through blood testing, which is urgently required to enable earlier diagnosis of Alzheimer’s disease.

Acronym 15HLT02 ReMiND (Reference Number: 15HLT02)
Duration 01/07/2016 - 01/07/2019
Project Topic Metrology
Project Results
(after finalisation)
See Website
Website visit project website
Network EMPIR
Call EMPIR CALL 2015

Project partner

Number Name Role Country
1 Physikalisch-Technische Bundesanstalt Coordinator Germany
2 Bundesanstalt fuer Materialforschung und -pruefung Partner Germany
3 LGC Limited Partner United Kingdom
4 Turkiye Bilimsel ve Teknolojik Arastirma Kurumu Partner Turkey
5 Charite - Universitaetsmedizin Berlin Partner Germany
6 Universiteit Gent Partner Belgium
7 The University Court of the University of Aberdeen Partner United Kingdom
8 Universitat Wien Partner Austria